Introduction
IgA nephropathy (IgAN) was first described by Berger and Hinglais in 1968. However, no particular pathogenic cause has been elucidated in human IgAN. IgAN is characterized by its features : IgA is predominantly deposited in glomeruli with various grades of mesangial proliferation in every patient, and serum IgA levels are elevated in nearly half of IgAN patients. It is also known that IgA specific regulatory lymphocytes are well represented in the mucosal immune system and IgA production is initiated primarily in this system. In light of these facts, I
hypothesized that IgAN is triggered by some exogenous antigen(s) which induces dysregulation of the mucosal immune system. One more remarkable feature of IgAN is that the apparent incidence of this disease varies greatly from country to country.
The disease is particularly prevalent in southern Europe, Southeast Asia, and Australia. In Japan, IgAN is the most common form of glomerulonephritis and the incidence of this disorder amounts to about 30 to 40 percent of patients with primary glomerulonephritis who underwent renal biopsy. In 1989, Pestka and colleagues reported that an environmental mycotoxin, deoxynivalenol (DON), induces some pathological changes in mice which resemble human IgAN.
It has been pointed out, however, that common agricultural products such as corn and oats were more commonly contaminated with nivalenol (NIV) than with DON in Southeast Asia and Japan where IgAN is more frequently found. NIV (3, 4, 7, 15-tetrahydroxy-12, 13-epoxy trichothecene 9-en-8-on) was first isolated in Japan from the metabolites of Fusarium nivale Fn 2B as a causal agent of scabby wheat intoxication in 1968. Thus, based on the mucosal immunity-oriented hypothesis of IgAN and the more frequent occurrence of this disease in Southeast Asia and Japan as described above, I thought it meaningful to determine whether orally-ingested NIV can, in fact, induce pathological changes in glomeruli of mice, which resemble those in human IgAN. It was further examined whether immunological alterations of lymphocytes isolated from Peyer's patches (PP), an important IgA inductive site or gut-associated lymphoid tissues (GALT), occured in the NIV-induced IgAN after
we established the NIV model. Japan (Tokyo, Japan). For NIV administration, mice were fed semi-synthetic diets containing 6 or 12 ppm NIV for 4 or 8 weeks. Control mice were fed on the same semi-synthetic diets without NIV. All mice were given these diets ad lib. For comparison, a part of mice were orally given ferritin (Sigma Chemical Co., St. Louis, MO) at 10 mg in 0.2 ml by gastric intubation on the first day, followed by 1 mg/ml of drinking water for 4 wk by the modified method of Genin and colleagues.
After completion of the oral presentations, the levels of IgG, IgM and IgA in the sera were determined by enzyme-linked immunosorbent assay (ELISA)
Sections of renal cortex were examined by immunofluorescence for glomerular immunoglobulin and C3 deposition, and by light and electron micoscopy for histopathological changes.
Once it was established that orally administered NIV induced IgAN-like changes, a competitive ELISA was carried out to confirm whether or not the IgA antibody from the model mice truly has affinity to NIV. Adoptive transfer of PPL from the standard model mice were also carried out using six-to eight-week-old normal syngeneic mice as recipients.
Moreover, an enzymelinked immunospot (ELISPOT) assay was performed to evaluate the number of antibodyproducing cells in the standard NIV model. RT (reverse transcription)-PCR (polymerase chain reaction) analysis was performed as well to detect cytokine-specific mRNA expressions of CD4+ T cells isolated from PP in the model mice. In all of these immunological studies, C3H/HeN mice fed NIV 12 ppm for 8 weeks were used as the model mice.
Differences between different study groups of mice were analyzed by Student's t-test or by
Mann-Whitney U test for nonparametric analyses.
Establishment of the NIV Model
Oral administration of NIV in low doses reproducibly induced significant IgA deposits in glomerular mesangium and elevated serum IgA levels in C3H/HeN mice ( Fig. 1 and 2 ). Mesangial IgA deposition was the most intense and serum IgA level was the most highly elevated in mice given NIV 12 ppm for 8 weeks. These changes were confirmed in mice irrespective of the strain.
Namely, oral administration of NIV 12 ppm for 8 weeks also caused both significant Furthermore, a competitive ELISA with a NIV analogue-protein conjugate disclosed that the IgA antibody in sera from the NIV model mice had a higher affinity to the mycotoxin (Fig. 3) .
Conclusively, these findings suggest that NIV induces some pathological changes in mice which the model mice by cytokine-specific RT-PCR technique, where markedly high levels of mRNA specific for IL-4, IL-5, IL-6, IL-10 and TGF-/3 were noted in these cells (Fig. 5) . The expressions of IL-4, IL-5, IL-6, IL-10 and TGF-/3 specific mRNA were also elevated in CD4+ T cells isolated from the SPL of the model mice fed with NIV 12 ppm for 8 weeks just as in those of the PPL, though the expressions were slightly less intense in CD4+ T cells of the SPL.
Given all of these facts above, it is suggested that PPL are immunologically dysregulated in the NIV-induced IgAN, and that this kind of upregulation of the mucosal immune system may be associated with the pathogenesis of IgAN. This finding indicates that NIV must be considered as a possible causative agent in human IgAN.
Moreover, it is reasonable to hypothesize that IgAN is triggered by some exogenous antigen(s) which induces dysregulation of the mucosal immune system, according to the present results. It was also demonstrated that lymphocytes of the PP, the immunologically major working force and inductive site in GALT, were dysregulated in this NIV model.
